

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Brii Biosciences Limited**  
**騰盛博药生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2137)**

**VOLUNTARY ANNOUNCEMENT**  
**APPOINTMENTS OF CHIEF TECHNOLOGY OFFICER AND**  
**CNS DISEASES THERAPY AREA HEAD**

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce the appointments of Dr. Eleanor (Ellee) de Groot Ph.D. (“**Dr. de Groot**”), as the Senior Vice President, Chief Technology Officer of the Company and Dr. Aleksandar Skuban M.D. (“**Dr. Skuban**”), as the Vice President, Central Nervous System (“**CNS**”) Diseases Therapy Area Head of the Company, with effect from August 15, 2022 and August 23, 2022, respectively.

“Dr. de Groot and Dr. Skuban are both seasoned biotech leaders with impressive credentials and an entrepreneurial history of leading medicine development and manufacturing initiatives within their functional areas. We are excited to welcome them to the Company’s team as we continue to advance our pipeline of innovative drug candidates on behalf of patients facing significant health burdens around the world,” said Dr. Zhi Hong, Ph.D., the Chairman and the Chief Executive Officer of the Company. “With experience spanning all phases in the making of medicines, Dr. de Groot is an important addition to our executive team as we execute against our broad therapeutic modalities. Likewise, Dr. Skuban’s deep expertise in CNS and mental health clinical development and patient care will be essential as we prioritize the advancement of our lead U.S. therapeutic programs in postpartum depression and major depressive & anxiety disorders.”

**Dr. de Groot, Ph.D., the Senior Vice President, Chief Technology Officer of the Company**

Dr. de Groot has more than two decades of experience leading a wide range of streamlined global operations across growing biotechnology companies, from early to late stage clinical development and commercial-scale manufacturing. Dr. de Groot held key leadership roles during her career with Alaunos Therapeutics, Inc., most recently serving as Executive Vice President of Operations where she oversaw the development of novel cell therapy programs and led clinical manufacturing, quality and process development. In addition, during her extended tenure at Helsinn Therapeutics, Inc., Dr. de Groot held multiple roles of increasing responsibility within chemistry, manufacturing, and controls processes management where she directed preparations for drug product commercialization, including global regulatory engagement, technology transfers and collaborations with key business partners worldwide. Dr. de Groot holds both a Ph.D. and a Master of Science degree in chemical engineering from Stanford University in the U.S., a Bachelor of Science degree in chemical engineering from Massachusetts Institute of Technology in the U.S. and a Master of Business Administration from Rice University in the U.S.

“I believe the Company’s diversified pipeline of promising therapeutic candidates shows great potential to address some of the biggest public health challenges of our time, and I’m eager to contribute my expertise to support ongoing product development and generate a sustainable long-term growth strategy within the Company,” said Dr. de Groot, the Senior Vice President, Chief Technology Officer of the Company.

**Dr. Skuban, M.D., the Vice President, CNS Diseases Therapy Area Head of the Company**

Dr. Skuban brings to the Company more than 25 years of global pharmaceutical research and development experience with an extensive medical, scientific and business leadership track record of achievements, including leading more than 30 studies across therapeutic areas from early-stage proof of concept through positive regulatory outcomes, with a focus on CNS diseases. Previously, Dr. Skuban served as Senior Vice President of Clinical Development at Better Therapeutics, Inc., where he shaped research strategy to enable rapid development of new indications for prescription digital therapeutics. Prior to that, he served as an Executive Medical Director leading clinical development within Alexion Pharmaceuticals, Inc.’s emerging ophthalmology therapeutic area. At Otsuka Pharmaceuticals Co., Ltd, Dr. Skuban’s tenure included roles overseeing various clinical portfolios, notably guiding to U.S. Food and Drug Administration’s approval for Brexpiprazole (REXULTI) for major depressive disorder and schizophrenia. Dr. Skuban also held a number of clinical development director roles at Merck & Co., Inc and Sanofi-Aventis, Inc. He obtained a Doctor of Medicine degree from Semmelweis University of Medicine in Budapest, Hungary and attended the School of Medicine at the University of Novi Sad, School of Medicine in Novi Sad, Yugoslavia (Serbia).

“I am inspired by the meaningful patient-centric approach that the Company has cultivated in the earliest stages of clinical planning. I look forward to incorporating unique patient insights into the Company’s CNS programs to ensure our investigational treatments are well-positioned for the future of mental healthcare and grounded in the fundamental understanding of patient’s preference and needs,” said Dr. Skuban, the Vice President, CNS Diseases Therapy Area Head of the Company.

By order of the Board  
**Brii Biosciences Limited**  
**Dr. Zhi Hong**  
*Chairman*

Hong Kong, August 23, 2022

*As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.*